A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
This pilot clinical trial studies fludeoxyglucose F18 (FDG)-positron emission tomography
 (PET) in imaging patients with prostate cancer treated with ranolazine. Diagnostic
 procedures, such as FDG-PET, may help find prostate cancer and find out how far the disease
 has spread. Giving ranolazine may enhance FDG-PET imaging by increasing the amount of glucose
 available for uptake by the scan.
PET scans have traditionally not been very good at detecting prostate cancers. This is
 because prostate cancer cells do not take up glucose well so the signals are very weak. The
 ability of PET imaging to detect cancers requires that the cancer cells take up glucose into
 the cells. Different methods are being tested to see if we can improve the detection of
 prostate cancers using PET scans.

 Ranolazine is a drug that is already approved by the FDA for treatment of chronic chest pain
 in people with heart disease. Ranolazine has been studied in the laboratories at the
 University of Colorado Denver, Anschutz Medical Campus. Ranolazine has been added to prostate
 cancer cells and grown in petri dishes and in animals in the laboratory. It has been shown to
 increase the glucose uptake of prostate cancer cells. The goal of this study is to see if
 patients taking ranolazine will have better PET imaging of their prostate cancers.
Inclusion Criteria:

 1. Written informed consent has been obtained.

 2. Adults over 18 years of age.

 3. Histological or cytologically confirmed prostate adenocarcinoma.

 4. Arm 1 patients must have treatment-naïve, Gleason ≥ 7 prostate cancer based on
 transrectal ultrasound (TRUS) biopsy, have localized disease, and have decided to
 undergo radical prostatectomy (open or robotic) as definitive treatment for their
 prostate cancer.

 5. Arm 2 patients must have lymph node, soft tissue, bone, or visceral metastatic disease
 measuring ≥ 1 cm (lytic component if bone), documented by either CT or MRI imaging
 within 6 weeks of signing consent. Arm 2 patients may have hormone-sensitive or
 castrate-resistant disease and may be receiving treatment with hormonal therapies.

 6. For Arm 1 patients, the time from the TRUS prostate biopsy to the planned first study
 PET scan must be ≥ 1 month. For patients who have undergone prior prostate mapping
 biopsy, the time from the mapping biopsy to the planned first study PET scan must be ≥
 2 months.

 7. For Arm 1 patients, participation in this study, in the opinion of the treating
 physicians, will not introduce delays in surgery that would adversely affect the
 patient.

 8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

 9. Fasting blood glucose ≤ 120 mg/dL.

 10. Adequate renal function (Creatinine ≤ 1.5 X ULN)

 11. Adequate hepatic function (bilirubin < 1.5 X upper limit of normal (ULN), alanine
 aminotransferase (ALT) < 1.5 X ULN, aspartate aminotransferase (AST) < 1.5 X ULN, and
 albumin ≥ 3 g/dL. For patients with known bone metastases, alkaline phosphatase < 5 X
 ULN is acceptable.

 12. Must be able to take oral medication without crushing, dissolving or chewing tablets.

 13. Written authorization for use and release of health and research study information has
 been obtained.

 14. Patients who have partners of childbearing potential must be willing to use a method
 of birth control with adequate barrier protection during the study and for 1 week
 after the last dose of ranolazine.

 Exclusion Criteria:

 1. Have small cell carcinoma or neuroendocrine component >50%.

 2. Have a history of gastrointestinal disorders (medical disorders or extensive surgery)
 that may interfere with the absorption of ranolazine.

 3. Documented hypersensitivity to any component of ranolazine (Ranexa®) pills.

 4. Need for medications that are:

 1. strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors (e.g.
 ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir,
 indinavir, saquinavir),

 2. moderate CYP3A inhibitors (e.g. diltiazem, verapamil, erythromycin, fluconazole,
 grapefruit juice or grapefruit-containing products),

 3. CYP3A inducers (e.g. rifampin, rifabutin, rifapentine, phenobarbital, phenytoin,
 carbamazepine, St. John's wort),

 4. CYP3A substrates with a narrow therapeutic range (e.g. cyclosporine, tacrolimus,
 sirolimus),

 5. P-gp inhibitors or substrates (e.g. cyclosporine, digoxin),

 6. polypeptide 6 (CYP2D6) substrates (e.g. tricyclic antidepressants and
 antipsychotics),or

 7. simvastatin at doses > 20 mg/day.

 5. Have corrected QT interval (QTc)> 450 msec (male) or > 470 msec (female) on 12-lead
 electrocardiogram.

 6. Poorly controlled diabetes, hemoglobin A1c (Hgb A1C) >9 or random blood glucose
 >250mg/dL.

 7. Active or symptomatic viral hepatitis or chronic liver disease.

 8. Clinically significant heart disease as evidenced by:

 1. myocardial infarction, or

 2. arterial thrombotic events in the past 6 months,

 3. severe or unstable angina, or

 4. New York Heart Association Class III-IV heart disease or

 5. cardiac ejection fraction measurement of <50%.

 9. Active infection requiring antibiotics.

 10. Major surgery or radiation treatment within 3 months.

 11. Cytotoxic chemotherapy within 4 weeks.

 12. Immunotherapy within 6 months.

 13. Any prior therapy with Radium-223, Samarium, or Strontium.

 14. Arm 1 patients may not have received any prior luteinizing-hormone-releasing hormone
 (LHRH) agonists/antagonists, anti-androgens, or chemotherapy for their prostate
 cancer. 5-alpha reductase inhibitors (finasteride, dutasteride) may be allowed.

 15. Have any condition that, in the opinion of the investigator, would compromise the
 well-being of the subject or the study or prevent the subject from meeting or
 performing study requirements.